On January 27, 2017, Spotlight Innovation Inc. (the Company) entered into a second Exclusive License Agreement (the License Agreement) with Florida State University Research Foundation to commercialize certain compounds that may have therapeutic potential for treating viral infections, including Zika virus infection. The Company will file a copy of the License Agreement with its Annual Report on Form 10-K for the year ended December 31, 2016 in redacted form subject to an application for confidential treatment the Company is making with the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SPOTLIGHT INNOVATION INC.
Dated: January 31, 2017
/s/ John Krohn
President and Chief Operating Officer
makes a similar move, sign up!
Other recent filings from the company include the following: